- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00895180
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Monoclonal antibodies, such as ramucirumab and anti-PDGFR alpha monoclonal antibody IMC-3G3 (Olaratumab), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
PURPOSE: This phase II trial is studying how well ramucirumab or anti-PDGFR alpha monoclonal antibody IMC-3G3 works in treating patients with recurrent glioblastoma multiforme.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- To assess the progression-free survival rate at 6 months after treatment with ramucirumab or anti-PDGFR alpha monoclonal antibody IMC-3G3 in patients with recurrent glioblastoma multiforme.
Secondary
- To evaluate the acute and late toxicities associated with these regimens.
- To assess the objective tumor response rate.
- To estimate the overall survival of these patients.
- To describe the pharmacokinetic and pharmacodynamic profiles and immunogenicity of these regimens.
OUTLINE: This is a multicenter study. Patients are sequentially assigned to 1 of 2 treatment groups.
- Group 1: Patients receive ramucirumab IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
- Group 2: Patients receive anti-PDGFR alpha monoclonal antibody IMC-3G3 IV over 60-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294-3410
- Uab Comprehensive Cancer Center
-
-
California
-
Los Angeles, California, United States, 90095
- Jonsson Comprehensive Cancer Center at UCLA
-
San Francisco, California, United States, 94143
- University of California San Francisco Medical Center
-
-
Florida
-
Tampa, Florida, United States, 33612-9497
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
-
-
Maryland
-
Baltimore, Maryland, United States, 21231-2410
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Josephine Ford Cancer Center at Henry Ford Hospital
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157-1096
- Wake Forest University Comprehensive Cancer Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Taussig Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh School of Medicine
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed supratentorial glioblastoma multiforme (GBM)
- Patients with prior low-grade glioma who progressed after radiotherapy ± chemotherapy and are biopsied and found to have GBM are eligible
- Progressive or recurrent disease after radiotherapy ± chemotherapy
- Measurable disease by contrast-enhanced MRI or CT scan
PATIENT CHARACTERISTICS:
- Karnofsky performance status 60-100%
- Life expectancy ≥ 3 months
- Absolute neutrophil count ≥ 1,500/millimeter cubed (mm³)
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 9 gram/deciliter (g/dL)
- Creatinine ≤ 1.5 milligram/deciliter (mg/dL) OR creatinine clearance > 60 mL/min
- Total bilirubin ≤ 1.5 mg/dL
- Transaminases ≤ 3 times upper limit of normal (ULN)
- Urine protein ≤ 2+ by dipstick or urinalysis or ≤ 1,000 mg by 24-hour urine collection
- International Normalized Ratio (INR) ≤ 1.5
- Partial Thromboplastin Time (PTT) ≤ 5 seconds above ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for ≥ 12 weeks after completion of study treatment
- Mini Mental State Exam score ≥ 15
- Able to undergo magnetic resonance imaging (MRI) (i.e., no pacemaker, aneurysm clip, or claustrophobia)
No concurrent serious infection or medical illness that would jeopardize the ability of the patient to receive the treatment outlined in this study with reasonable safety including, but not limited to, any of the following:
- Uncontrolled hypertension
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Psychiatric illness/social situation that would limit compliance with study requirements
- No other malignancy within the past 5 years, except curatively treated carcinoma in situ or basal cell carcinoma of the skin
- No major bleeding episode within the past 3 months
- No myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack within the past 6 months
- No serious or non-healing wound, ulcer, or bone fracture
- No uncontrolled or poorly controlled hypertension, despite standard medical management
- No known allergy to any of the treatment components
- No known HIV positivity or AIDS-related illness
- No uncontrolled thrombotic or hemorrhagic disorders
- No grade 3-4 gastrointestinal bleeding within the past 3 months
- No gross hemoptysis (≥ ½ teaspoon) within the past 2 months
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from prior therapy
- At least 3 months since prior radiotherapy
- At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)
- At least 2 weeks since prior FDA-approved, non-cytotoxic agents (e.g., celecoxib, thalidomide)
- At least 3 weeks since prior investigational, non-cytotoxic agents
- More than 28 days since prior major surgery, including brain biopsy
- More than 7 days since prior subcutaneous venous access device placement
- No prior treatment with other agents that directly inhibit Platelet-Derived Growth Factor Receptor (PDGFR)α/β, Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), or Vascular Endothelial Growth Factor Receptor (VEGFR)s
- No concurrent therapeutic anticoagulation, chronic daily treatment with aspirin (> 325 mg/day), or other known inhibitors of platelet function
- No concurrent prophylactic hematopoietic growth factors (e.g., erythropoietin, Granulocyte Colony Stimulating Factor (G-CSF), Granulocyte-macrophage Colony Stimulating Factor (GM-CSF), or Interleukin (IL-11) during the first course of treatment
- No concurrent elective or planned surgery
No other concurrent therapy for the tumor (e.g., chemotherapy or investigational agents)
- Concurrent steroids allowed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Patients receive ramucirumab IV over 1 hour on day 1.
Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
|
Given IV
|
Experimental: Group 2
Patients receive olaratumab IV over 60-90 minutes on day 1.
Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Achieved Progression-Free Survival Rate at 6 Months (PFS-6)
Time Frame: Start of treatment to PD or Death Up To 6 Months
|
PFS was defined as the start of treatment to the earliest date of tumor progression or death from any cause based on the modified Response Assessment in Neuro-Oncology Group through the American Society of Clinical Oncology (RANO) criteria.
Progression is defined by any of the following: ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions; any new lesion; or clinical deterioration.
RANO is a standardized response criteria using bi-dimensional measurements of the largest contrast-enhancing area (Macdonald, 1990).
|
Start of treatment to PD or Death Up To 6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events as Assessed by NCI CTCAE v4.0 (National Cancer Institute-Common Terminology Criteria for Adverse Events)
Time Frame: Start of Treatment to End of Study (Up to 13 Months)
|
The number of participants who experienced serious adverse events (SAEs) that were considered to be related to ramucirumab or olaratumab.
A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
|
Start of Treatment to End of Study (Up to 13 Months)
|
Percentage of Participants (Pts) With Complete Response (CR), Partial Response (PR) and Minor Response (MR) (Objective Response Rate [ORR])
Time Frame: Start of Treatment to PD Up To 20 Months
|
The pts achievement of both measurement and confirmation criteria for a status of CR, PR or MR based on the modified RANO criteria.CR requires all of the following:complete disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks (wks);no new lesions;no corticosteroids;and stable or improved clinically.PR requires all of the following:≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 wks;no new lesions;stable or reduced corticosteroid dose;and stable or improved clinically.MR requires ≥ 25% reduction in sum of products of the perpendicular diameters of all measureable enhancing lesions sustained for at least 4 wks and no new lesions or progression of non-measurable lesions.
PD is defined by any of these: ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions;any new lesion;or clinical deterioration.
|
Start of Treatment to PD Up To 20 Months
|
Median Overall Survival (OS)
Time Frame: Start of Treatment to Death Up To 27 Months
|
OS is the time from the start of treatment to the date of death.
Participants who had not expired by the data analysis cutoff date were censored at their last date known to be alive.
|
Start of Treatment to Death Up To 27 Months
|
Pharmacokinetics (PK): Concentration Maximum (Cmax) and Concentration Minimum (Cmin) of Ramucirumab
Time Frame: Cycle 7, Day 1: Prior to Infusion,1 hour (hr) Post Infusion
|
Cycle 7, Day 1: Prior to Infusion,1 hour (hr) Post Infusion
|
|
PK: Cmax and Cmin of Olaratumab
Time Frame: Cycle 3, Day 1: Prior to Infusion, 1 hr Post Infusion
|
Cycle 3, Day 1: Prior to Infusion, 1 hr Post Infusion
|
|
Pharmacodynamics (PD) Profiles
Time Frame: Cycle 7, Day 1: Prior to Infusion, 1 hr Post Infusion
|
Cycle 7, Day 1: Prior to Infusion, 1 hr Post Infusion
|
|
Percentage of Participants With Anti-Olaratumab Antibodies (ADA)
Time Frame: Start of Treatment to 30-day Post Infusion Follow Up (Up to 6 Months)
|
Percentage of Participants with Treatment Emergent (TE) anti-olaratumab antibodies were participants with a 4-fold increase (2 dilutions) increase over a positive baseline antibody titer or for a negative baseline titer, a participant with an increase from the baseline to a level of 1:20.
|
Start of Treatment to 30-day Post Infusion Follow Up (Up to 6 Months)
|
Percentage of Participants With Anti-Ramucirumab Antibodies (ADA)
Time Frame: Start of Treatment to 30-day Post Infusion Follow Up (Up to 6 Months)
|
Percentage of Participants with Treatment Emergent (TE) anti-ramucirumab antibodies were participants with a 4-fold increase (2 dilutions) increase over a positive baseline antibody titer or for a negative baseline titer, a participant with an increase from the baseline to a level of 1:20.
|
Start of Treatment to 30-day Post Infusion Follow Up (Up to 6 Months)
|
Collaborators and Investigators
Investigators
- Study Chair: Jaishri O. Blakeley, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABTC-0901 CDR0000641230
- U01CA137443 (U.S. NIH Grant/Contract)
- ABTC-0901
- IMCL-CP-19-0801
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Glioblastoma Multiforme
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Sunnybrook Health Sciences CentreRecruitingGlioblastoma Multiforme, AdultCanada
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingGlioblastoma Multiforme, AdultChina
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Nader SanaiBeiGene; Barrow Neurological Institute; Ivy Brain Tumor CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, AdultUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, AdultUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
Clinical Trials on ramucirumab
-
Shanghai Henlius BiotechTerminatedHealthy Male VolunteersChina
-
Yonsei UniversityNot yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedGastric Cancer | Non-small Cell Lung Cancer | Colo-rectal CancerChina
-
Eli Lilly and CompanyParexelCompleted
-
Yale UniversityWithdrawnTransitional Cell CarcinomaUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompleted
-
Samsung Medical CenterRecruiting
-
Eli Lilly and CompanyCompletedHepatocellular CarcinomaUnited States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
-
Eli Lilly and CompanyCompletedHepatocellular CarcinomaUnited States